IL2 and acute lymphoblastic leukemia: Subsequently, the opportunity to document similar enhancement of GvL effects by IL-2-activated DLI following super-myeloablative conditioning and allogeneic SCT from a fully matched sibling was confirmed in late 1986 when a patient with fully resistant relapsed ALL following super-myeloablative conditioning was rescued with IL-2 activated DLI after failing to respond to treatment with naïve donor lymphocytes (Slavin and Nagler 1991; Slavin et al. 1995).